Abstract
Pulmonary arterial hypertension (PAH) is a rare disease characterized by a dramatic, progressive rise of pulmonary vascular resistance (PVR), leading to elevated pulmonary artery pressures, right ventricular (RV) overload, and, eventually, failure. Current evaluation of PAH is based on invasive hemodynamics (RHC), exercise capacity, echocardiography, and N-terminal pro brain natriuretic peptide (NT-proBNP) levels [ [1] Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC) European Respiratory Society (ERS) International Society of Heart and Lung Transplantation (ISHLT) et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009; 34: 1219-1263 Crossref PubMed Scopus (1091) Google Scholar ]; although published survival data support a strong clinical role for cardiac magnetic resonance imaging (CMR) of the RV, this technique is still underused [ [2] Bradlow W.M. Gibbs J.S. Mohiaddin R.H. Cardiovascular magnetic resonance in pulmonary hypertension. J Cardiovasc Magn Reson. 2012; 14: 6 Crossref PubMed Scopus (53) Google Scholar ]. Much research is currently focusing on the exploration of candidate soluble biomarkers of RV dysfunction and prognosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
